Table 1. Demographic and clinical characteristics of participants 3 years after cessation of placebo or postmenopausal hormone therapy
VariableOriginal treatment groupP‐value
PL (n = 26)oCEE (n = 18)tE2 (n = 23)
Age, yr60 (59, 62)61 (59, 62)60 (59, 61)0.731
Body mass index, kg/m227 (25, 31)27 (24, 29)27 (22, 33)0.893
Heart rate, bpm65 (54, 70)61 (57, 63)64 (53, 67)0.848
Peripheral SBP, mm Hg123 (115, 131)123 (117, 130)124 (119, 128)0.916
Peripheral DBP, mm Hg74 (67, 83)75 (71, 79)75 (70, 79)0.914
Mean arterial pressure, mm Hg88 (83, 100)91 (86, 96)91 (86, 95)0.959
Low‐density lipoprotein cholesterol, mg/dL123 (113, 144)120 (106, 132)117 (91, 140)0.765
High‐density lipoprotein cholesterol, mg/dL60 (54, 67)64 (58, 75)68 (56, 75)0.473
Triglycerides, mg/dL94 (73, 115)104 (83, 119)83 (69, 109)0.395
Fasting glucose, mg/dL94 (88, 98)97 (92, 100)93 (89, 100)0.458
Insulin, μIU/mL5 (4, 7)6 (4, 7)4 (3, 6)0.095
Number taking antihypertensive medications, n (%)5 (19%)3 (17%)1 (4%)0.280
Number taking aspirin, n (%)5 (19%)4 (22%)4 (17%)0.927
Number taking hormone therapy at present study, n (%)7 (27%)5 (28%)7 (30%)0.962
Oral, n021
Transdermal, n113
Vaginal, n611
Oral+Transdermal, n011
Buccal, n001
  • Data are presented as median (25th, 75th percentile), unless otherwise noted. bpm, beats per minute; DBP, diastolic blood pressure; mm Hg, millimeters of mercury; oCEE, oral conjugated equine estrogen; SBP, systolic blood pressure; tE2, transdermal 17β‐estradiol.